Tirzepatide (Zepbound) produces the greatest average weight loss of any available GLP-1 medication — roughly 20–22% of body weight — but semaglutide (Wegovy) and the new oral options work meaningfully well for many patients and cost significantly less. The right choice depends on your weight-loss goal, needle preference, schedule, insurance situation, and whether you have conditions like type 2 diabetes or cardiovascular disease that favor one drug’s profile. No single GLP-1 is best for everyone; what matters is matching the drug’s strengths to your specific priorities.

If you have been comparing Wegovy, Ozempic, Zepbound, Mounjaro, the Wegovy pill, and the new Foundayo tablet, this guide breaks down the 2026 clinical evidence in plain language so you can have a more informed conversation with your provider.

Should I take semaglutide or tirzepatide?

This is the most common GLP-1 question providers hear in 2026, and the clinical answer is nuanced.

In the 72-week SURMOUNT-5 trial — the first large, head-to-head randomized study directly comparing the two drugs — tirzepatide produced a mean body-weight reduction of 20.2% versus 13.7% for semaglutide (NEJM / Applied Clinical Trials, 2025). Participants on tirzepatide were also significantly more likely to hit the 15%, 20%, and 25% weight-loss benchmarks.

A 2026 meta-analysis of seven studies covering 28,980 participants confirmed this pattern: tirzepatide consistently outperformed semaglutide on total weight reduction and glycemic control (Frontiers in Medicine, 2026).

Why the difference? Semaglutide activates one receptor — GLP-1 — which slows gastric emptying and reduces appetite. Tirzepatide activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual mechanism appears to deliver additive effects on satiety and metabolic rate, explaining the roughly 6–7 percentage-point gap in average weight loss.

However, tirzepatide is not automatically the superior choice for every patient:

  • Semaglutide has more mature cardiovascular data. The SELECT trial (NEJM, 2023) showed semaglutide reduced major adverse cardiovascular events by 20% in people without diabetes who had obesity and established heart disease — a benefit that has not yet been fully established for tirzepatide in a comparable population.
  • Tirzepatide produced lower rates of nausea (~31%) than semaglutide (~44%) at doses producing equivalent weight loss, which may improve tolerability for some patients.
  • Semaglutide is available as a weekly injection or a daily pill (oral semaglutide 25 mg, FDA-approved December 2025), giving it a delivery-format advantage.

How does the new oral GLP-1 pill compare to injections?

Two oral GLP-1 options are now FDA-approved in the United States:

Oral semaglutide (Wegovy pill, 25 mg) — approved December 22, 2025. In the OASIS 4 Phase III trial, participants achieved a mean weight loss of 16.6% at 64 weeks, closely matching injectable Wegovy’s 14.9% in the STEP 1 trial (NEJM, 2021). The pill must be taken once daily on an empty stomach, at least 30 minutes before the first food, beverage, or other oral medication of the day.

Orforglipron (Foundayo) — approved April 1, 2026. The first small-molecule, non-peptide GLP-1 agonist. In the ATTAIN trial program, Foundayo produced approximately 11% body-weight loss over 72 weeks at the highest dose (FDA prescribing information, April 2026). Crucially, it can be taken at any time of day, with or without food or water — no fasting window required. This makes it especially practical for patients with unpredictable schedules.

Neither oral option matches injectable tirzepatide’s 20%+ average weight loss in head-to-head terms, but both deliver clinically meaningful results — especially for patients who cannot or will not self-inject.

2026 GLP-1 Comparison: Semaglutide vs. Tirzepatide vs. Oral Pills

MedicationBrandRouteAvg. Weight LossDosingApprox. Monthly Cost (brand)Key Advantage
Semaglutide 2.4 mgWegovyWeekly injection~14–15%Once weekly~$299 (NovoCare direct)Strongest CV data; once weekly
Tirzepatide 5–15 mgZepboundWeekly injection~20–22%Once weekly~$550 (LillyDirect)Greatest weight loss; dual-agonist
Oral semaglutide 25 mgWegovy pillDaily pill~16.6%Once daily (fasting)Similar to injectable WegovyNo needles; near-injection efficacy
Orforglipron (orforglipron)FoundayoDaily pill~11%Once daily (any time)TBD (2026 launch pricing)No fasting, no needles; flexible
Compounded semaglutide*VariousWeekly injection~14–15%Once weekly~$178/monthLowest out-of-pocket
Compounded tirzepatide*VariousWeekly injection~20–22%Once weekly~$278/monthDual-agonist at lower price

*Compounded versions are available through licensed 503B pharmacies. Availability and legality vary; confirm with your provider. See our guide on compounded semaglutide and the 2026 FDA ruling.

What are the side effects of semaglutide vs. tirzepatide?

Both drugs share the same class of GI side effects: nausea, vomiting, diarrhea, and constipation. These are most common during dose escalation and typically lessen over 4–8 weeks as your body adjusts.

Key differences to know:

  • Nausea: Approximately 44% of semaglutide users report nausea at therapeutic doses versus ~31% for tirzepatide — a meaningful difference for patients who are sensitive to GI symptoms (Frontiers in Medicine, 2026).
  • Muscle loss: Both drugs cause some lean-muscle loss alongside fat loss. This is a class-wide effect, not unique to either agent. Adequate protein intake (at least 1.2–1.6 g per kg of body weight daily) and resistance training can substantially offset this. See our guide on preserving muscle on a GLP-1.
  • Pancreatitis and thyroid concerns: Both carry class warnings for a rare risk of pancreatitis and, in animal studies only, a signal for thyroid C-cell tumors. Neither drug is recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2.
  • Gallbladder: Rapid weight loss with any GLP-1 increases the risk of gallstones. Both drugs carry this risk equally.

Does insurance or Medicare cover GLP-1 medications in 2026?

Coverage varies significantly by medication and plan:

  • Commercial insurance: Wegovy and Zepbound coverage depends on your employer or plan. Many large employers added GLP-1 benefits in 2024–2025, but exclusions remain common. Prior authorization typically requires a BMI ≥ 30 or ≥ 27 with a qualifying comorbidity.
  • Medicare: The Medicare GLP-1 Bridge pilot (launched July 1, 2026) covers semaglutide and tirzepatide for qualifying beneficiaries at approximately $50/month. Coverage remains limited by income and plan type.
  • Manufacturer programs: NovoCare’s Wegovy savings card reduces brand Wegovy to ~$299/month for commercially insured patients who meet income limits. LillyDirect’s Zepbound Savings Card reduces brand Zepbound to ~$550/month for eligible patients.
  • Telehealth programs: For cash-pay patients, compounded semaglutide through licensed telehealth programs starts around $178/month; compounded tirzepatide around $278/month.

For a full breakdown, see our 2026 insurance and Medicare GLP-1 coverage guide.

Which GLP-1 is right for me?

There is no single correct answer — your provider will weigh several factors:

Choose semaglutide (Wegovy injection or pill) if you:

  • Have established cardiovascular disease and want the drug with the strongest CV outcomes data
  • Prefer a weekly injection or want the pill option with near-injection efficacy
  • Are cost-sensitive and not on insurance that covers tirzepatide
  • Have had intolerable GI symptoms on tirzepatide in the past

Choose tirzepatide (Zepbound) if you:

  • Want maximum average weight loss and are prepared for the higher cost
  • Have type 2 diabetes (both semaglutide and tirzepatide are approved for diabetes as Ozempic/Mounjaro, but tirzepatide shows greater A1c reduction)
  • Found semaglutide’s nausea difficult to manage

Choose an oral GLP-1 (Wegovy pill or Foundayo) if you:

  • Have a needle phobia or strong aversion to self-injection
  • Travel frequently or have an unpredictable schedule (Foundayo’s no-fasting advantage)
  • Are comfortable accepting somewhat lower average weight loss in exchange for convenience

Talk to a provider if any of the above applies. GLP-1 selection, dosing, and monitoring require clinical judgment — starting on the wrong dose or without appropriate follow-up can slow progress or worsen side effects.

Omnia TeleHealth’s weight loss program includes an async consultation, prescription, and ongoing clinical check-ins so your provider can adjust your plan as you progress. Most patients complete their intake in under 10 minutes and receive a response within 24 hours.

Frequently Asked Questions

Is tirzepatide always better than semaglutide? On average weight loss in clinical trials, tirzepatide outperforms semaglutide — 20.2% vs. 13.7% in the SURMOUNT-5 head-to-head trial. But semaglutide has stronger cardiovascular outcome data, is available in pill form, and costs less. “Better” depends on your priorities.

Can I switch from semaglutide to tirzepatide? Yes, many patients switch. Providers typically restart the dose titration at the lowest dose of tirzepatide rather than converting directly, because the two drugs have different dose-effect profiles. Switching should be supervised by a clinician.

Does the Wegovy pill work as well as the Wegovy injection? Clinical trial results are similar — 16.6% weight loss for the pill (OASIS 4) versus 14.9% for the injection (STEP 1) — though these are different trials, not a direct head-to-head. The main caveat is the fasting requirement: the pill must be taken 30 minutes before any food or drink for best absorption.

What is Foundayo and how does it differ from the Wegovy pill? Foundayo (orforglipron) is a small-molecule, non-peptide oral GLP-1 approved April 2026. Unlike the Wegovy pill, it can be taken any time of day with or without food. It produced about 11% weight loss in trials — less than the Wegovy pill’s 16.6%, but meaningful. Its main advantage is convenience and flexibility.

Can a telehealth provider prescribe GLP-1 medications? Yes. Licensed telehealth providers can evaluate your eligibility, prescribe semaglutide or tirzepatide, and send your prescription to a pharmacy or 503B compounding pharmacy. Omnia TeleHealth’s weight loss program includes medical evaluation, prescription, and ongoing follow-up — all online, without an office visit.